Clinical Trial Detail

NCT ID NCT02750514
Title An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Dasatinib + Nivolumab

Nivolumab + Relatlimab

Nivolumab

BMS-986205 + Nivolumab

Age Groups: adult senior

No variant requirements are available.